Cidara Therapeutics, Inc. (CDTX)
Jan 7, 2026 - CDTX was delisted (reason: acquired by MRK)
221.38
+0.06 (0.03%)
Inactive · Last trade price on Jan 6, 2026
Cidara Therapeutics Employees
Cidara Therapeutics had 38 employees as of December 31, 2024. The number of employees decreased by 31 or -44.93% compared to the previous year.
Employees
38
Change (1Y)
-31
Growth (1Y)
-44.93%
Revenue / Employee
n/a
Profits / Employee
-$4,861,526
Market Cap
6.97B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 38 | -31 | -44.93% | 38 | 0 |
| Dec 31, 2023 | 69 | -4 | -5.48% | 69 | 0 |
| Dec 31, 2022 | 73 | -16 | -17.98% | 73 | 0 |
| Dec 31, 2021 | 89 | 9 | 11.25% | 89 | 0 |
| Dec 31, 2020 | 80 | 12 | 17.65% | 79 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
CDTX News
- 2 months ago - Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations - GlobeNewsWire
- 2 months ago - Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025 - Forbes
- 2 months ago - Merck expects over $5 billion commercial opportunity from Cidara's flu drug - Reuters
- 2 months ago - Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga
- 2 months ago - Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX - Business Wire
- 2 months ago - This Biotech's Stock Price More Than Doubled on Friday. Here's Why. - Investopedia
- 2 months ago - This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy - Market Watch
- 2 months ago - Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approaches - Invezz